论文部分内容阅读
目的探讨外源性胰高血糖样素肽-1治疗对糖尿病伴高血压患者血压变异性的影响。方法选择2型糖尿病伴高血压患者179例,随机分为对照组90例,研究组89例。对照组仅采用常规治疗,研究组在常规治疗基础上采用利拉鲁肽注射治疗,比较两组治疗6个月后血压变异性的变化。结果治疗6个月后研究组24 h平均收缩压、24 h收缩压变异性、白昼收缩压变异性、夜间收缩压变异性显著低于对照组(P<0.05)。治疗6个月后研究组较对照组夜间收缩压下降百分率显著增加,非杓型血压患者比率显著降低(P<0.05)。结论外源性胰高血糖样素肽-1可降低糖尿病伴高血压患者的血压变异性与非杓型血压患者比率。
Objective To investigate the effect of exogenous glucagon-like peptide-1 on blood pressure variability in patients with diabetes and hypertension. Methods 179 patients with type 2 diabetes mellitus and hypertension were randomly divided into control group (n = 90) and study group (n = 89). The control group was treated with routine therapy only. The study group received liraglutide injection on the basis of routine treatment. The changes of blood pressure variability after 6 months treatment were compared between the two groups. Results After 6 months of treatment, the average systolic blood pressure at 24 hours, systolic blood pressure at 24 hours, systolic blood pressure variability at daytime, and systolic blood pressure variability at night were significantly lower in the study group than those in the control group (P <0.05). After 6 months of treatment, the percentage of decrease in nocturnal systolic pressure was significantly increased in the study group compared with the control group, and the percentage of non-dipper blood pressure group was significantly decreased (P <0.05). Conclusion Exogenous glucagon-like peptide-1 can reduce the ratio of blood pressure variability and non-dipper blood pressure in patients with diabetes mellitus and hypertension.